2019 Update to: Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)

The American Diabetes Association and the European Association for the Study of Diabetes have briefly updated their 2018 recommendations on management of hyperglycemia, based on important research findings from large cardiovascular outcomes trials published in 2019. Important changes include: 1) the decision to treat high-risk individuals with a glucagon-like peptide 1 (GLP-1) receptor agonist or sodium–glucose cotransporter 2 (SGLT2) inhibitor to reduce major adverse cardiovascular events (MACE), hospitalization for heart failure (hHF), cardiovascular death, or chronic kidney disease (CKD) progression should be considered independently of baseline HbA1c or individualized HbA1c target; 2) GLP-1 receptor…

• AD
  American Diabetes Association
• EL
  Eli Lilly and Company
• A
  AstraZeneca
• G
  GlaxoSmithKline
• S
  Sanofi
• CB
  CSL Behring
• MC
  MannKind Corporation
• EF
  European Foundation for the Study of Diabetes
• NN
  Novo Nordisk
• EA
  European Association for the Study of Diabetes
• NI
  National Institutes of Health

  Award: UL1TR002489
• NI
  National Institute of Diabetes and Digestive and Kidney Diseases
• DO
  Division of Diabetes, Endocrinology, and Metabolic Diseases